JP2017503810A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503810A5 JP2017503810A5 JP2016545917A JP2016545917A JP2017503810A5 JP 2017503810 A5 JP2017503810 A5 JP 2017503810A5 JP 2016545917 A JP2016545917 A JP 2016545917A JP 2016545917 A JP2016545917 A JP 2016545917A JP 2017503810 A5 JP2017503810 A5 JP 2017503810A5
- Authority
- JP
- Japan
- Prior art keywords
- ectodomain
- ntb
- subject
- cell
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925265P | 2014-01-09 | 2014-01-09 | |
| US61/925,265 | 2014-01-09 | ||
| PCT/IL2015/050033 WO2015104711A1 (en) | 2014-01-09 | 2015-01-08 | Improved cell compositions and methods for cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020053791A Division JP7004761B2 (ja) | 2014-01-09 | 2020-03-25 | 癌治療のための改善された細胞組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503810A JP2017503810A (ja) | 2017-02-02 |
| JP2017503810A5 true JP2017503810A5 (https=) | 2018-02-22 |
| JP6682438B2 JP6682438B2 (ja) | 2020-04-15 |
Family
ID=53523593
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545917A Active JP6682438B2 (ja) | 2014-01-09 | 2015-01-08 | 癌治療のための改善された細胞組成物および方法 |
| JP2020053791A Active JP7004761B2 (ja) | 2014-01-09 | 2020-03-25 | 癌治療のための改善された細胞組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020053791A Active JP7004761B2 (ja) | 2014-01-09 | 2020-03-25 | 癌治療のための改善された細胞組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10344073B2 (https=) |
| EP (2) | EP3091999B2 (https=) |
| JP (2) | JP6682438B2 (https=) |
| AU (1) | AU2015205327B2 (https=) |
| CA (1) | CA2935903A1 (https=) |
| ES (1) | ES2902835T3 (https=) |
| IL (1) | IL246607B (https=) |
| WO (1) | WO2015104711A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10780080B2 (en) * | 2016-11-23 | 2020-09-22 | Translational Drug Development, Llc | Benzamide and active compound compositions and methods of use |
| CN107502589A (zh) * | 2017-08-04 | 2017-12-22 | 北京世纪劲得生物技术有限公司 | 一种肿瘤浸润淋巴细胞与单个核细胞共培养方法 |
| US11110171B2 (en) | 2017-12-21 | 2021-09-07 | New York University | PD-1 related cancer therapy |
| WO2019145956A1 (en) * | 2018-01-25 | 2019-08-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods for improved immunotherapy |
| JP7458318B2 (ja) * | 2018-02-12 | 2024-03-29 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | 癌治療のためのｓｌａｍｆ６スプライスバリアントの調節 |
| IL267614A (en) * | 2019-06-24 | 2019-09-26 | Lotem Michal | Nucleic acids to modulate SLAMF6 isoforms |
| AU2020298833A1 (en) | 2019-07-03 | 2022-01-20 | Oxford Biotherapeutics Ltd | Antibodies and methods of use |
| EP4146205A4 (en) | 2020-05-05 | 2024-05-29 | Nuvalent, Inc. | HETEROAROMATIC MACROCYCLIC ETHERS AS CHEMOTHERAPEUTIC AGENTS |
| IL297832A (en) | 2020-05-05 | 2023-01-01 | Nuvalent Inc | Macrocyclic heteroaromatic chemotherapeutic agents |
| TW202320768A (zh) | 2021-10-01 | 2023-06-01 | 美商努法倫特公司 | 雜芳族大環醚化合物之固體形式、醫藥組成物及製備 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US7479269B2 (en) * | 1988-11-23 | 2009-01-20 | Genetics Institute, Llc | Methods for selectively enriching TH1 and TH2 cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5719867A (en) | 1995-06-30 | 1998-02-17 | Scientific-Atlanta, Inc. | Plural telephony channel baseband signal demodulator for a broadband communications system |
| US6284267B1 (en) | 1996-08-14 | 2001-09-04 | Nutrimed Biotech | Amphiphilic materials and liposome formulations thereof |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| EP2213743A1 (en) | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050054051A1 (en) | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7138243B2 (en) | 2001-07-19 | 2006-11-21 | Innate Pharma, S.A. | NTB-A, a surface molecule involved in natural killer cells activity |
| MXPA04001986A (es) | 2001-08-29 | 2004-06-07 | Genentech Inc | Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad. |
| US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| JP2005206478A (ja) | 2004-01-20 | 2005-08-04 | Kirin Brewery Co Ltd | 樹状細胞膜分子−ＩｇＦｃ融合ポリペプチドまたはそれに対する抗体を含む医薬組成物 |
| US7592313B2 (en) * | 2004-05-17 | 2009-09-22 | Board Of Trustees Of The University Of Illinois | Method of stimulating proliferation of regulatory T cells in a diabetic mammal |
| EP1642905B1 (en) | 2004-10-02 | 2009-01-21 | Immatics Biotechnologies GmbH | Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes |
| CA2604844A1 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics, Inc. | Cancer-related genes |
| EP1916302A4 (en) * | 2005-08-17 | 2009-10-21 | Takara Bio Inc | PROCESS FOR THE PRODUCTION OF LYMPHOCYTES |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| TW200823237A (en) * | 2006-08-28 | 2008-06-01 | Nuvelo Inc | Antibodies to NTB-A |
| EP2222277A4 (en) | 2007-11-15 | 2014-10-15 | Biolitec Pharma Ip & Invest Ltd | PEGYLATED LIPOSOMAL FORMULATIONS FOR PHOTODYNAMIC TREATMENT OF INFLAMMATORY DISEASES |
| US20120244133A1 (en) * | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| IL267614A (en) | 2019-06-24 | 2019-09-26 | Lotem Michal | Nucleic acids to modulate SLAMF6 isoforms |
-
2015
- 2015-01-08 WO PCT/IL2015/050033 patent/WO2015104711A1/en not_active Ceased
- 2015-01-08 JP JP2016545917A patent/JP6682438B2/ja active Active
- 2015-01-08 AU AU2015205327A patent/AU2015205327B2/en active Active
- 2015-01-08 US US15/110,111 patent/US10344073B2/en active Active
- 2015-01-08 ES ES15734922T patent/ES2902835T3/es active Active
- 2015-01-08 EP EP15734922.6A patent/EP3091999B2/en active Active
- 2015-01-08 CA CA2935903A patent/CA2935903A1/en active Pending
- 2015-01-08 EP EP21197303.7A patent/EP4101461A1/en active Pending
-
2016
- 2016-07-05 IL IL246607A patent/IL246607B/en unknown
-
2019
- 2019-05-20 US US16/417,048 patent/US11530251B2/en active Active
-
2020
- 2020-03-25 JP JP2020053791A patent/JP7004761B2/ja active Active
-
2022
- 2022-11-10 US US18/054,346 patent/US20230078665A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503810A5 (https=) | ||
| Liang et al. | Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell–mediated killing | |
| Piper et al. | Glioma stem cells as immunotherapeutic targets: advancements and challenges | |
| EP2100615B1 (en) | Cancer therapy | |
| JP6899333B2 (ja) | 汎用キラーｔ細胞 | |
| Spaas et al. | Is the combination of immunotherapy and radiotherapy in non-small cell lung cancer a feasible and effective approach? | |
| US10918638B2 (en) | Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination | |
| Chang et al. | Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors | |
| Draghiciu et al. | Therapeutic immunization and local low‐dose tumor irradiation, a reinforcing combination | |
| JP2010529026A5 (https=) | ||
| Reijmen et al. | Fractionated radiation severely reduces the number of CD8+ T cells and mature antigen presenting cells within lung tumors | |
| JPH09501174A (ja) | キラー細胞媒介細胞融解に対するガン細胞の増感方法 | |
| Plavc et al. | Combining radiotherapy and immunotherapy in definitive treatment of head and neck squamous cell carcinoma: review of current clinical trials | |
| Catani et al. | Intratumoral immunization by p19Arf and interferon-β gene transfer in a heterotopic mouse model of lung carcinoma | |
| Pan et al. | Synthesized natural peptides from amphibian skin secretions increase the efficacy of a therapeutic vaccine by recruiting more T cells to the tumour site | |
| TWI759270B (zh) | 藉由t細胞療法治療多發性骨髓瘤及漿細胞白血病之方法 | |
| JP5435938B2 (ja) | ワクチン接種のための天然ペプチド及びそれらの最適化された誘導体の使用 | |
| WO2020163782A2 (en) | Immunotherapy for the treatment and prevention of inflammatory bowel disease | |
| Suginobe et al. | Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors | |
| Narita et al. | WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase | |
| CN103097398B (zh) | 免疫原性肽以及包含该肽的用于预防或治疗hpv相关疾病的组合物 | |
| Gewirtz et al. | The potentially conflicting cell autonomous and cell non-autonomous functions of autophagy in mediating tumor response to cancer therapy | |
| CN108524918B (zh) | 一种抗肿瘤组合物及其表达载体和应用 | |
| Hao et al. | Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors | |
| Cayssials et al. | Beyond tyrosine kinase inhibitors: Combinations and other agents |